15th February 2021 Dosing commenced in US ACTIV-2 trial
25th January 2021 Inclusion in US ACTIV-2 trial
20th January 2021 Home trial recruitment completed
13th January 2021 First Patient Dosing in Phase III SG018 Trial
18th December 2020 COVID-19 Clinical Programme Update
13th November 2020 Lancet Respiratory Medicine publishes Phase 2 data
2nd November 2020 Result of General Meeting and Total Voting Rights
2nd November 2020 Result of Open Offer
15th October 2020 Results of Placing
14th October 2020 Placing and Open Offer
2nd October 2020 Appointment of Joint Broker
29th September 2020 Interim results for the six months ended 30 June 2020
29th September 2020 Synairgen and Clinigen sign Managed Access Program agreement with SNG001 for treatment of hospitalised patients with COVID-19
9th September 2020 Synairgen IP Update
8th September 2020 Positive interim analysis of SNG001 in COPD
21st July 2020 Clarification Regarding COVID-19 Trial
20th July 2020 Positive results from trial of SNG001 in hospitalised COVID-19 patients
29th June 2020 Result of AGM
18th June 2020 National expansion of home-based COVID-19 trial
3rd June 2020 Posting of Annual Report and Notice of AGM
28th May 2020 Recruitment of Hospitalised Patients in COVID-19 Trial Completed
26th May 2020 Initiation of SNG001 in home setting
26th May 2020 Preliminary statement of results for the year ended 31 December 2019
30th April 2020 Approval received to extend SG016 study of SNG001 in COVID-19 to initiate patients in the home environment
14th April 2020 Result of General Meeting
31st March 2020 Commencement of dosing in COVID-19 trial
26th March 2020 Result of fundraising
25th March 2020 Proposed fundraising
18th March 2020 Synairgen to start trial of SNG001 in COVID-19 imminently
30th September 2019 Interim results for the six months ended 30 June 2019
27th September 2019 Phase II Biomarker Data for SNG001 to be presented at European Respiratory Society
24th July 2019 Phase II Clinical Trial Update in Patients with COPD
3rd June 2019 Result of AGM
18th April 2019 Directorate Change, Posting of Annual Report, and Notice of AGM
14th March 2019 Positive DSMC Review of Phase II Study for SNG001
25th February 2019 Preliminary statement of results for the year ended 31 December 2018
17th January 2019 Update on LOXL2 programme with Pharmaxis
22nd October 2018 Synairgen commences dosing in part 2 of its Phase II clinical trial in patients with COPD
12th October 2018 Result of General Meeting
25th September 2018 Result of Fundraise
25th September 2018 Proposed Fundraise to raise c.£2.9 million
25th September 2018 Interim results for the six months ended 30 June 2018
28th June 2018 Positive SNG001 Biomarker Data in COPD Patients
22nd June 2018 Result of Synairgen AGM
22nd June 2018 Synairgen Safety Data with SNG001 in COPD Patients
17th May 2018 Posting of Annual Report and Notice of AGM
15th March 2018 Preliminary statement of results for the year ended 31 December 2017
7th February 2018 Synairgen starts dosing in phase II COPD study
27th December 2017 Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD
14th December 2017 Update on LOXL2 Programme and Collaboration with Pharmaxis
27th September 2017 Interim results for the six months ended 30 June 2017
6th September 2017 LOXL2 Inhibitor Update
28th June 2017 Result of 2017 Annual General Meeting
5th June 2017 Posting of Annual Report and Notice of AGM
17th May 2017 Preliminary statement of results for the year ended 31 December 2016
27th April 2017 AZD9412 Update
10th March 2017 Additional Positive Data in Lung Fibrosis
12th October 2016 AZD9412 Clinical Trial Update
22nd September 2016 Interim results for the six months ended 30 June 2016
8th September 2016 Notice of Interim Results
14th June 2016 Results of 2016 Annual General Meeting
17th May 2016 Posting of Annual Report and Notice of AGM
22nd March 2016 Preliminary statement of results for the year ended 31 December 2015
22nd March 2016 Positive LOXL2 results
3rd March 2016 Notice of Preliminary Results
16th September 2015 Interim results for the six months ended 30 June 2015
21st August 2015 Notice of Interim Results
5th August 2015 Research collaboration with Pharmaxis in IPF
2nd July 2015 AstraZeneca commences AZD9412 Phase II trial in severe asthma
22nd June 2015 Results of 2015 Annual General Meeting
15th May 2015 Notice of Annual General Meeting
22nd April 2015 Posting of Annual Report and Accounts
3rd March 2015 Preliminary statement of results for the year ended 31 December 2014
25th September 2014 Interim results for the six months ended 30 June 2014
17th September 2014 Notice of Interim Results